These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19704052)

  • 1. Classification of Philadelphia translocation-negative myeloproliferative neoplasms: its impact on data from clinical trials.
    Naresh KN
    J Clin Oncol; 2009 Nov; 27(31):e175-6; author reply e177-8. PubMed ID: 19704052
    [No Abstract]   [Full Text] [Related]  

  • 2. The WHO 2008 classification of Ph-myeloproliferative disorders: statement of the Czech MPD Working Group.
    Schwarz J; Penka M; Indrák K; Pospísilová D; Pytlík R; Dulícek P; Doubek M; Kren L; Campr V;
    Leukemia; 2008 Nov; 22(11):2118-9. PubMed ID: 18418405
    [No Abstract]   [Full Text] [Related]  

  • 3. Philadelphia chromosome-negative chronic myeloproliferative disease.
    Thiele J
    Am J Clin Pathol; 2009 Aug; 132(2):261-80. PubMed ID: 19605821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hematologic phenotype versus cytogenic phenotype in 124 chronic myeloproliferative syndromes (1979-1987)].
    Sánchez-Fayos MP; Outeiriño J; Benítez J; Calabuig T; Prieto E; Sánchez-Guilarte J; Bosch JM; Rodríguez C; Sánchez-Fayos J
    Sangre (Barc); 1988 Dec; 33(6):491-6. PubMed ID: 3247625
    [No Abstract]   [Full Text] [Related]  

  • 6. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
    Anastasi J
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reduction of Ph1 chromosome in atypical myeloproliferative disorder by intensive chemotherapy].
    Takeyama H; Yano K; Fukutani H; Yamamoto F; Watanabe E; Satake T
    Rinsho Ketsueki; 1986 Sep; 27(9):1640-4. PubMed ID: 3468279
    [No Abstract]   [Full Text] [Related]  

  • 8. [Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society CLS JEP ].
    Penka M; Schwarz J; Campr V; Pospíšilová D; Křen L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulíček P; Jonášová A; Kissová J; Kořístek Z; Schützová M; Vonke I; Walterová L;
    Vnitr Lek; 2012 Feb; 58(2):163-8. PubMed ID: 22463098
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the Côte d'Or area, France, during 1980-99.
    Girodon F; Jooste V; Maynadie M; Favre B; Schaeffer C; Carli P
    J Intern Med; 2005 Jul; 258(1):90-1. PubMed ID: 15953137
    [No Abstract]   [Full Text] [Related]  

  • 10. Age at diagnosis is an important prognostic factor in Philadelphia-negative Myeloproliferative Neoplasms.
    Accurso V; Santoro M; Siragusa S
    Eur J Haematol; 2019 Aug; 103(2):140-141. PubMed ID: 31121064
    [No Abstract]   [Full Text] [Related]  

  • 11. [The polymorphism of myeloproliferative tumor processes].
    Brilliant MD; Domracheva EV; Tikhonova LIu; Vorob'ev AI
    Ter Arkh; 1988; 60(5):3-9. PubMed ID: 3175925
    [No Abstract]   [Full Text] [Related]  

  • 12. Dysregulation of shelterin factors coupled with telomere shortening in Philadelphia chromosome negative myeloproliferative neoplasms.
    Dahlström J; Zhang X; Ghaderi M; Hultcrantz M; Björkholm M; Xu D
    Haematologica; 2015 Oct; 100(10):e402-5. PubMed ID: 26185173
    [No Abstract]   [Full Text] [Related]  

  • 13. [Classification for myeloproliferative neoplasms and function of novel mutations].
    Kirito K
    Rinsho Ketsueki; 2011 Oct; 52(10):1575-84. PubMed ID: 21971234
    [No Abstract]   [Full Text] [Related]  

  • 14. Reclassification of subtypes in Philadelphia chromosome-negative myeloproliferative neoplasm by 2016 WHO diagnostic criteria: focus on the cases classified as myeloproliferative neoplasm, unclassifiable by the 2008 version.
    Yun J; Kim JA; Park J; Im K; Lee YE; Jeong D; Ryu S; Lim KM; Kim SM; Ahn YO; Lee DS
    Leuk Lymphoma; 2020 Dec; 61(14):3498-3502. PubMed ID: 32876501
    [No Abstract]   [Full Text] [Related]  

  • 15. Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?
    Barosi G; Tefferi A; Barbui T;
    Leukemia; 2012 May; 26(5):1148-9. PubMed ID: 22105597
    [No Abstract]   [Full Text] [Related]  

  • 16. Myeloproliferative neoplasms: an overview.
    Finnegan K
    Clin Lab Sci; 2011; 24(3):178-82. PubMed ID: 21905584
    [No Abstract]   [Full Text] [Related]  

  • 17. Myeloproliferative neoplasms: the role of molecular markers.
    Collins L
    Clin Lab Sci; 2011; 24(3):183-6. PubMed ID: 21905585
    [No Abstract]   [Full Text] [Related]  

  • 18. Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma.
    Sameeta F; Fang H; Wang W; Tang Z; Wang SA; Toruner GA; Parisi X; Khoury JD; Issa G; Garcia-Manero G; Medeiros LJ; Tang G; Loghavi S
    Am J Hematol; 2024 Sep; 99(9):1827-1829. PubMed ID: 38440855
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version.
    Iurlo A; Gianelli U; Cattaneo D; Thiele J; Orazi A
    Am J Hematol; 2017 Apr; 92(4):E48-E51. PubMed ID: 28109016
    [No Abstract]   [Full Text] [Related]  

  • 20. Philadelphia chromosome-negative myeloproliferative disorders: an historical perspective.
    Prchal JT
    Hematology Am Soc Hematol Educ Program; 2008; ():68. PubMed ID: 19074060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.